References

Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: current challenges and therapeutic options

10.1111/bjh.18656 · 2023 · External reference

Sequencing of anti-CD19 therapies in the management of diffuse large B-cell lymphoma

10.1158/1078-0432.ccr-23-1962 · 2024 · External reference

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

10.1182/blood.2021010930 · 2021 · External reference

CD19-loss with preservation of other B cell lineage features in patients with large B cell lymphoma who relapsed post-axi-cel

10.1182/blood-2019-126218 · 2019 · External reference

Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy

10.1182/blood.2020006245 · 2021 · External reference

Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy

10.1158/2159-8290.cd-15-1020 · 2015 · External reference

Fine epitope mapping of the CD19 extracellular domain promotes design

10.1021/acs.biochem.9b00808 · 2019 · External reference

CD19 isoforms enabling resistance to CART-19 immunotherapy are expressed in B-ALL patients at initial diagnosis

10.1097/cji.0000000000000169 · 2017 · External reference

Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking

10.1182/blood-2016-05-718395 · 2017 · External reference

Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency

10.1172/jci175199 · 2024 · External reference

Hypermethylation of CD19 promoter enables antigen-negative escape to CART-19 in vivo and in vitro

10.1136/jitc-2021-002352 · 2021 · External reference

CD19-negative relapse after CAR-T cell therapy: mechanisms of antigen escape and lineage switch

10.3389/fimmu.2026.1692287 · 2026 · External reference

Unresolved reference

External reference

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody

10.1016/b978-0-323-35762-3.00077-9 · 2010 · External reference

Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia

10.1158/0008-5472.can-08-2268 · 2008 · External reference

CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas

10.1080/10428194.2021.1992622 · 2022 · External reference

Expression of CD19 antigen on chronic lymphocytic leukemia cells after tafasitamab (anti-CD19) treatment: phase I trial data

10.1182/blood-2019-128613 · 2019 · External reference

CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study

10.1080/10428194.2021.1986219 · 2022 · External reference

CD19 expression in diffuse large B-cell lymphoma (DLBCL) patient biopsies after treatment with tafasitamab

10.1200/jco.2024.42.16_suppl.e19050 · 2024 · External reference

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

10.1016/s1470-2045(20)30225-4 · 2020 · External reference

A phase 3 study of tafasitamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (firmMIND)

10.1182/blood-2022-160319 · 2022 · External reference

Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial

10.1016/s0140-6736(25)01778-7 · 2026 · External reference

Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: A systematic review and meta-analysis

10.1016/j.jtct.2023.10.017 · 2024 · External reference

Effectiveness and safety of chimeric antigen receptor T-cell (CAR-T) therapy after tafasitamab (Tafa) in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL): A real-world study

10.1002/hem3.70420 · 2026 · External reference

Preclinical study of CD19 detection methods post tafasitamab treatment

10.3389/fimmu.2023.1274556 · 2023 · External reference

Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma

10.1186/s40364-024-00706-6 · 2025 · External reference

Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy

10.1182/bloodadvances.2024013726 · 2024 · External reference